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Age-related macular degeneration (AMD) is 
the most common cause of legal blindness 
among the elderly in developed countries. 
The prevalence of advanced forms of AMD 
is increasing; it is expected to rise by 50% 
by the year 2020 in the United States. Early 
identification of AMD susceptibility and 
implementation of preventive measures are 
important management strategies. Antibodies 
against vascular endothelial growth factor 
(VEGF) have become the treatment of choice 
in patients with choroidal neovascularization 
(CNV); however, substantial improvement of 
vision occurs only in approximately one-third 
of patients. Early diagnosis and treatment of 
CNV may increase the success rate of treatment. 
Standard diagnostic modalities including 
fundus angiography and optical coherence 
tomography can detect CNV in clinical stages 
when vision is affected. In a novel approach, 
Takeda and coworkers evaluated the role of an 
eosinophil/mast cell chemokine receptor, CCR3, 
in CNV. They studied CCR3 expression among 
patients with AMD and previously untreated 
surgically excised CNV membranes, donor eyes 
of age-matched non-AMD controls, atrophic 
AMD, uveal melanoma, and surgically excised 
epiretinal membranes. Additionally, in vivo 
CCR3 bioimaging was performed in transgenic 
mice with spontaneous CNV using intravenous 
quantum-dot labeled CCR3 antibody fragments 
followed by fundus fluorescent imaging 
which demonstrated hyperfluorescent signals 
in regions of the fundus that were silent on 
standard fluorescein angiography. These 
hyperfluorescent dots were subsequently 
confirmed to be CNVs using histologic 
examination. The investigators showed 
that CCR3 was specifically expressed in the 
endothelial cells of all human CNV membranes 
but not in other conditions. Interestingly, they 
found that CCR3 neutralization was superior 
to VEGF blockade in suppressing laser-induced 
CNV in mice. Considering emerging safety 
concerns about continual blockade of VEGF, 
which is constitutively expressed in the normal 
adult human retina and needed for retinal 
health, a treatment strategy based on more 
specific targeting of CNV would be desirable. 
These findings suggest that CCR3 targeting 
may be a viable strategy for early detection and 
treatment of CNV, and might be superior to 
the current standard of care. CCR3 bioimaging 
would probably be most useful in eyes at high 
risk for CNV such as multiple large drusen or 
sound fellow eyes of patients with clinically 
evident CNV; it can also serve as a useful tool 
for differentiating lesions mimicking CNV. 
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